Showing 2601-2610 of 7016 results for "".
Beyond IOP: Integrating Ocular Surface Resilience Into Glaucoma Management
https://reachmd.com/programs/cme/beyond-iop-integrating-ocular-surface-resilience-into-glaucoma-management/49097/Our experts discuss management strategies for individualized ocular surface rehabilitation while maintaining optimal IOP control in patients with glaucoma.Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
https://reachmd.com/programs/cme/safety-and-tolerability-of-cdh6-directed-antibody-drug-conjugates/37865/CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian CancerExploring the Latest in MS Cognitive Rehabilitation Strategies
https://reachmd.com/programs/neurofrontiers/exploring-the-latest-in-ms-cognitive-rehabilitation-strategies/18041/At what point in the MS process should we be providing cognitive rehabilitation to the patient? Tune in.Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
https://reachmd.com/programs/cme/clinical-implications-of-emerging-data-on-b7-h3directed-adcs-in-the-future-of-es-sclc/39979/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.Safety in oHCM Therapy: How and When to Transition Treatment?
https://reachmd.com/programs/cme/safety-in-ohcm-therapy-how-and-when-to-transition-treatment/56831/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Managing Margins Without Sacrificing Care
https://reachmd.com/programs/modern-optometry/managing-margins-without-sacrificing-care/39993/Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
https://reachmd.com/programs/cme/emerging-clinical-evidence-for-b7-h3directed-adcs-in-es-sclc-from-esmo-2025/39978/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
https://reachmd.com/programs/cme/guideline-recommendations-in-first-line-treatment-of-her2-negative-upper-gi-cancers/37689/Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-MakingData Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
https://reachmd.com/programs/cme/data-driving-recent-guideline-updates-in-neoadjuvant-therapy-for-resectable-melanoma/36322/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.GA Case Compendium: Identification of Geographic Atrophy on Color Fundus Photography
https://reachmd.com/resources/geographic-atrophy-case-compendium/ga-case-compendium-identification-of-geographic-atrophy-on-color-fundus-photography/56702/